The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …

The management of chronic conditions often requires patients to take daily medication for an
extended duration. However, the need for daily dosing can lead to nonadherence to the …

Long-acting formulations are designed to reduce dosing frequency and simplify dosing
schedules by providing an extended duration of action. One approach to obtain long-acting …

Long-acting cabotegravir (CAB) extends antiretroviral drug administration from daily to
monthly. However, dosing volumes, injection site reactions and health-care oversight are …

Ultra-long-acting integrase strand transfer inhibitors were created by screening a library of
monomeric and dimeric dolutegravir (DTG) prodrug nanoformulations. This led to an 18 …

Abstract Treatment and prevention of human immunodeficiency virus type one (HIV-1)
infection was transformed through widespread use of antiretroviral therapy (ART). However …

Worldwide, women face compounding reproductive health risks, including human
immunodeficiency virus (HIV), sexually-transmitted infections (STIs), and unintended …

The excellent properties of polyesters combined with their ease of synthesis and
modification enabled their wide use in the pharmaceutical industry. This has been translated …

In spite of introduction of combination antiretroviral therapy (cART) against human
immunodeficiency virus (HIV) infection; inaccessibility and poor adherence to oral cART …

Introduction Despite significant advances in treatment and prevention of HIV-1 infection,
poor adherence to daily combination antiretroviral therapy (ART) regimens remains a major …